Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial

Chemotherapy in combination with tyrosine kinase inhibitors (TKI) are effective in Ph+ ALL. Ponatinib is a third-generation TKI which potently inhibits the BCR-ABL tyrosine kinase. Single-agent ponatinib has high activity in patients with Ph+ ALL but has dose-dependent cardiovascular toxicity.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Abhishek Maiti, Hagop Kantarjian, Farhad Ravandi, Nicholas Short, Naval Daver, Naveen Pemmaraju, Deborah Thomas, Musa Yilmaz, Tapan Kadia, Koji Sasaki, Rebecca Garris, Guillermo Garcia-Manero, Courtney DiNardo, Marina Konopleva, Zeev Estrov, Nitin Jain, W Source Type: research